British climate tech company Levidian and Canadian graphene technology company Zentek have entered an agreement to explore the establishment of a new manufacturing facility in the Middle East.
The companies have agreed to combine their expertise in carbon capture, graphene production and materials development to accelerate the roll out of Zentek’s ZenGUARD™ Enhanced Air Filters and other graphene-enhanced products within the region, while also supporting the production of graphene for other industries.
Levidian’s patented LOOP system produces clean hydrogen and high-quality graphene by capturing carbon from methane before it’s burned, giving businesses the opportunity to both drive down emissions and boost the performance of their products. The graphene produced can be deployed in a wide range of products, from batteries and solar panels to tires and plastics. Levidian is already working to identify the location for a new production and delivery center in the region, which will serve as a showcase and central production hub for the business. The center is expected to create around 100 professional and manufacturing roles alongside a further 150 indirect jobs.
In March 2025, Levidian and Graphmatech partnered to advance graphene applications in the clean hydrogen field.
In addition, Zentek announced that it has completed the first phase of the Innovative Solutions Canada Testing Stream contract by delivering a lead candidate countermeasure for highly pathogenic avian influenza (HPAI) A(H5N1) and has now moved to the testing phase of the project. Zentek was awarded funding through the Government of Canada’s Innovative Solutions Canada (ISC) Testing Stream under Innovation, Science, and Economic Development Canada (“ISED”) for Health Advanced And Emerging Medical Technologies to develop both a prophylactic and therapeutic for avian influenza HPAI A(H5N1) using a multivalent aptamer strategy that previously led to the successful development of a SARS-CoV-2 aptamer. These efforts resulted in a lead candidate countermeasure that met the performance metrics established in the Government of Canada testing contract. The recent in vitro neutralization experiments demonstrated that the lead candidate countermeasure matched the performance of a monoclonal antibody positive control. The next phase of testing requires Zentek to deliver sufficient materials to Dr. Matthew Miller’s team at McMaster University, to evaluate the in vivo performance against H1N1 and the current clade of H5N1 influenza in circulation, H5N1 2.3.4.4b.
